MediciNova receives Notice of Allowance for new patent covering MN-166

MediciNova announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 for the treatment of chlorine-induced acute respiratory distress syndrome. Once issued, this patent is expected to expire no earlier than January 2042. The allowed claims cover the use of MN-166 for treating chlorine-induced ARDS. The allowed claims cover the use of MN-166 as a monotherapy or as a combination therapy with one or more other drugs. The allowed claims cover oral administration, intravenous administration, subcutaneous injection, intramuscular injection, and inhalation administration. The allowed claims cover a wide range of doses of MN-166, a range of different dosing frequencies, and a range of different treatment periods.